AngioDynamics Q4 2023 Earnings Report
Key Takeaways
AngioDynamics reported a 4.7% increase in net sales for the fourth quarter of fiscal year 2023, driven by growth in its Med Tech segment. The company's GAAP loss per share was $0.54, which included a goodwill impairment of $14.5 million. Adjusted earnings per share were $0.02. The company completed the sale of its Dialysis and BioSentry Biopsy businesses and provided FY24 guidance.
Net sales increased by 4.7% compared to the prior-year quarter, reaching $91.1 million.
Med Tech net sales grew by 17.2%, while Med Device net sales increased by 0.3%.
The company completed the sale of its Dialysis and BioSentry Tract Sealant System Biopsy businesses to Merit Medical Systems, Inc.
GAAP loss per share was $0.54, including a goodwill impairment, and adjusted earnings per share were $0.02.
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Forward Guidance
The Company expects its fiscal year 2024 net sales to be in the range of $328 to $333 million, gross margin to be approximately 50% to 52% and adjusted loss per share in the range of $0.28 to $0.34.
Revenue & Expenses
Visualization of income flow from segment revenue to net income